Exogenous porcine surfactants increase the infiltration of leukocytes in the lung of rats

Pulmonary Pharmacology and Therapeutics

Volumn 22, Issue 3, 2009, Pages 253-259

  Sun, Yu ^a   Wang, Yi Qun ^a   Yang, Rui ^a   Zhu, Jing Jing ^b   Le, Ying Ying ^b   Zhong, Ji Gen ^a   Lu, Jian ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b Chinese Academy of Sciences   (China)

Author keywords

Chemotaxis; Infiltration; Leukocytes; Lipopolysaccharide; Lung; Surfactant

Indexed keywords

DEXAMETHASONE; LUNG SURFACTANT; PORACTANT; TUMOR NECROSIS FACTOR ALPHA;

ACUTE LUNG INJURY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CHEMOTAXIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; LEUKOCYTE; LUNG INFILTRATE; LUNG LAVAGE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BRONCHOALVEOLAR LAVAGE FLUID; CHEMOTAXIS, LEUKOCYTE; DEXAMETHASONE; LEUKOCYTES; LIPOPOLYSACCHARIDES; LUNG; MALE; NEUTROPHIL INFILTRATION; PULMONARY SURFACTANTS; RATS; RATS, SPRAGUE-DAWLEY; SWINE;

EID: 67349175241     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2009.01.001     Document Type: Article

References (32)

1. Blanco O., and Perez-Gil J. Biochemical and pharmacological differences between preparations of exogenous natural surfactant used to treat respiratory distress syndrome: role of the different components in an efficient pulmonary surfactant. Eur J Pharmacol 568 (2007) 1-15
2. Maruscak A., and Lewis J.F. Exogenous surfactant therapy for ARDS. Expert Opin Investig Drugs 15 (2006) 47-58
3. Davidson W.J., Dorscheid D., Spragg R., Schulzer M., Mak E., and Ayas N.T. Exogenous pulmonary surfactant for the treatment of adult patients with acute respiratory distress syndrome: results of a meta-analysis. Crit Care 10 (2006) R41
4. Matthay M.A., and Zimmerman G.A. Acute lung injury and the acute respiratory distress syndrome: four decades of inquiry into pathogenesis and rational management. Am J Respir Cell Mol Biol 33 (2005) 319-327
5. Chen C.M., Fang C.L., and Chang C.H. Surfactant and corticosteroid effects on lung function in a rat model of acute lung injury. Crit Care Med 29 (2001) 2169-2175
6. Krause M.F., Wiemann T., Reisner A., Orlowska-Volk M., Kohler H., and Ankermann T. Surfactant reduces extravascular lung water and invasion of polymorphonuclear leukocytes into the lung in a piglet model of airway lavage. Pulm Pharmacol Ther 18 (2005) 129-139
7. Nieman G.F., Gatto L.A., Paskanik A.M., Yang B., Fluck R., and Picone A. Surfactant replacement in the treatment of sepsis-induced adult respiratory distress syndrome in pigs. Crit Care Med 24 (1996) 1025-1033
8. Scholtes U., Wiegand N., Zwirner J., and Herting E. Influence of porcine natural modified surfactant on chemotaxis and oxidative metabolism of polymorphonuclear leukocytes. Immunobiology 205 (2002) 290-302
9. Zhong J.G., Shen F.M., and Lu J. Therapeutic efficacy of intratracheal instillation of porcine surfactant in adult rabbits with lung lavage-induced acute respiratory distress syndrome. Chinese J Crit Care Med 26 (2006) 282-284
10. Sun Y., Huang J.X., Wang Y.Q., Zhong J.G., and Lu J. Influence of different doses of porcine pulmonary surfactant on the therapeutic effects in rats with oleic acid induced acute lung injury. Chinese J Crit Care Med 18 (2006) 470-473
11. Wang Y.Q., Sun Y., Yang R., Zhong J.G., and Lu J. Porcine surfactant in treatment of LPS-induced early-stage acute lung injury in rats. Chinese J Pathophysiol 23 (2007) 1583-1586
12. Johansson J., Curstedt T., and Robertson B. The proteins of the surfactant system. Eur Respir J 7 (1994) 372-391
13. Speer C.P., Robertson B., Curstedt T., Halliday H.L., Compagnone D., Gefeller O., et al. Randomized European multicenter trial of surfactant replacement therapy for severe neonatal respiratory distress syndrome: single versus multiple doses of Curosurf. Pediatrics 89 (1992) 13-20
14. Halliday H.L., Speer C.P., and Robertson B. Treatment of severe meconium aspiration syndrome with porcine surfactant. Collaborative Surfactant Study Group. Eur J Pediatr 155 (1996) 1047-1051
15. Lindena J., and Burkhardt H. Separation and chemiluminescence properties of human, canine and rat polymorphonuclear cells. J Immunol Methods 115 (1988) 141-147
16. Le Y., Ye R.D., Gong W., Li J., Iribarren P., and Wang J.M. Identification of functional domains in the formyl peptide receptor-like 1 for agonist-induced cell chemotaxis. FEBS J 272 (2005) 769-778
17. van Helden H.P., Kuijpers W.C., Langerwerf P.E., Langen R.C., Haagsman H.P., and Bruijnzeel P.L. Efficacy of Curosurf in a rat model of acute respiratory distress syndrome. Eur Respir J 12 (1998) 533-539
18. Zentay Z., Sharaf M., Qadir M., Drafta D., and Davidson D. Mechanism for dexamethasone inhibition of neutrophil migration upon exposure to lipopolysaccharide in vitro: role of neutrophil interleukin-8 release. Pediatr Res 46 (1999) 406-410
19. Penido C., Vieira-de-Abreu A., Bozza M.T., Castro-Faria-Neto H.C., and Bozza P.T. Role of monocyte chemotactic protein-1/CC chemokine ligand 2 on gamma delta T lymphocyte trafficking during inflammation induced by lipopolysaccharide or Mycobacterium bovis bacille Calmette-Guerin. J Immunol 171 (2003) 6788-6794
20. Irakam A., Miskolci V., Vancurova I., and Davidson D. Dose-related inhibition of proinflammatory cytokine release from neutrophils of the newborn by dexamethasone, betamethasone, and hydrocortisone. Biol Neonate 82 (2002) 89-95
21. Gao J.L., and Murphy P.M. Species and subtype variants of the N-formyl peptide chemotactic receptor reveal multiple important functional domains. J Biol Chem 268 (1993) 25395-25401
22. He R., Tan L., Browning D.D., Wang J.M., and Ye R.D. The synthetic peptide Trp-Lys-Tyr-Met-Val-D-Met is a potent chemotactic agonist for mouse formyl peptide receptor. J Immunol 165 (2000) 4598-4605
23. Nishiyama O., Kume H., Kondo M., Ito Y., Ito M., and Yamaki K. Role of lysophosphatidylcholine in eosinophil infiltration and resistance in airways. Clin Exp Pharmacol Physiol 31 (2004) 179-184
24. Brown S.L., Jala V.R., Raghuwanshi S.K., Nasser M.W., Haribabu B., and Richardson R.M. Activation and regulation of platelet-activating factor receptor: role of G(i) and G(q) in receptor-mediated chemotactic, cytotoxic, and cross-regulatory signals. J Immunol 177 (2006) 3242-3249
25. Gharavi N.M., Alva J.A., Mouillesseaux K.P., Lai C., Yeh M., Yeung W., et al. Role of the Jak/STAT pathway in the regulation of interleukin-8 transcription by oxidized phospholipids in vitro and in atherosclerosis in vivo. J Biol Chem 282 (2007) 31460-31468
26. Brogden K.A., De Lucca A.J., Bland J., and Elliott S. Isolation of an ovine pulmonary surfactant-associated anionic peptide bactericidal for Pasteurella haemolytica. Proc Natl Acad Sci U S A 93 (1996) 412-416
27. Harwig S.S., Kokryakov V.N., Swiderek K.M., Aleshina G.M., Zhao C., and Lehrer R.I. Prophenin-1, an exceptionally proline-rich antimicrobial peptide from porcine leukocytes. FEBS Lett 362 (1995) 65-69
28. Wang Y., Griffiths W.J., Curstedt T., and Johansson J. Porcine pulmonary surfactant preparations contain the antibacterial peptide prophenin and a C-terminal 18-residue fragment thereof. FEBS Lett 460 (1999) 257-262
29. Dias-Baruffi M., Roque-Barreira M.C., Cunha F.Q., and Ferreira S.H. Isolation and partial chemical characterization of macrophage-derived neutrophil chemotactic factor. Mediators Inflamm 4 (1995) 257-262
30. Dias-Baruffi M., Roque-Barreira M.C., Cunha F.Q., and Ferreira S.H. Biological characterization of purified macrophage-derived neutrophil chemotactic factor. Mediators Inflamm 4 (1995) 263-269
31. Cunha F.Q., and Ferreira S.H. The release of a neutrophil chemotactic factor from peritoneal macrophages by endotoxin: inhibition by glucocorticoids. Eur J Pharmacol 129 (1986) 65-76
32. Dias-Baruffi M., Cunha F.Q., Ferreira S.H., and Roque-Barreira M.C. Macrophage-released neutrophil chemotactic factor (MNCF) induces PMN-neutrophil migration through lectin-like activity. Agents Actions 38 (1993) Spec No:C54-6